Investors

Shareholder Tools

 

Overview

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company’s lead product candidate is HEPLISAV, an investigational adult hepatitis B vaccine. For more information visit www.dynavax.com

Recent Press Releases

Nov 10, 2014
Dynavax Announces Independent DSMB Recommendation to Continue Phase 3 Study of HEPLISAV-B(TM)

Nov 7, 2014
Dynavax Announces One-for-Ten Reverse Stock Split

View all releases »

E-Delivery of Stockholder Communications

Beneficial stockholders

Registered stockholders

Corporate Presentation

Annual Report and Proxy
2014 Proxy Statement
2013 Form 10-K